Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 9/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CCR6 | P51684 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28349583 | 0.92 | MGLL (0.41) | MGLLTLR9PSMB8PSMB5MAPK1 | |
| SCHEMBL11030785 | 0.86 | MGLL (0.51) | MGLLTLR9PSMB8PSMB5MAPK1 | |
| SCHEMBL9055859 | 0.81 | MGLL (0.37) | MGLLTLR9FAAH | |
| SCHEMBL157132 | 0.81 | MGLL (0.37) | MGLLTLR9FAAH | |
| SCHEMBL11032205 | 0.78 | GSK3A (0.43) | MGLLTLR9PSMB8PSMB5MAPK1 | |
| SCHEMBL43979 | 0.78 | MGLL (0.48) | MGLLMAPK1ALDH1A1HSP90AA1PKM | |
| SCHEMBL487779 | 0.77 | MGLL (0.57) | MGLLTLR9MAPK1ALDH1A1HSP90AA1 | |
| SCHEMBL8198691 | 0.76 | MGLL (0.46) | MGLLMAPK1ALDH1A1HSP90AA1PKM | |
| SCHEMBL1231930 | 0.76 | HDAC1 (0.50) | MAPK1TDP1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL16819519 | 0.76 | CYP4F2 (0.46) | PSMB8PSMB5ALDH1A1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10953073-B2 | XTEN conjugate compositions and methods of making same | AMUNIX PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | claimed |
| US-20040014124-A1 | Method for examining reactivity and method for detecting a complex | CANON KABUSHIKI KAISHA (JP) | 2004-01-22 | — | — | US | claimed |
| EP-1352976-A2 | Method of spotting probe on solid support, probe array and method of manufacturing thereof, and method of detecting target substance and method of identifying structure of target substance using probe array | CANON KABUSHIKI KAISHA (JP) | 2003-10-15 | — | — | EP | claimed |
| US-20030190612-A1 | Detecting method and detection substrate for use therein | CANON KABUSHIKI KAISHA (JP) | 2003-10-09 | — | — | US | claimed |
| EP-0895082-B1 | Bubble jet method for spotting probes on a solid support and method of manufacturing probe arrays. | CANON KK (JP) | 2003-09-24 | — | — | EP | claimed |
| US-20030059817-A1 | Spotting probe can bind preferentially to target nucleotide squences on solid support; provide liquid containing probe, deposit on solid support, form spot of probe on solid support | OKAMOTO TADASHI (JP) | 2003-03-27 | — | — | US | claimed |
| US-20030022227-A1 | Hybridization substrate for use in genome analysis and bacterial detection | RIKEN (JP) | 2003-01-30 | — | — | US | claimed |
| EP-1279434-A2 | Hybridization substrate, method of manufacturing same, and method of use for same | Riken (JP) | 2003-01-29 | — | — | EP | claimed |
| US-20020146715-A1 | Spotting probe preferentially bound to solid support; obtain liquid containing probe, apply to surface of solid support, allow stain to form on solid support | OKAMOTO TADASHI (JP) | 2002-10-10 | — | — | US | claimed |
| EP-0895082-A2 | Method of spotting probe on solid support, probe array and method of manufacturing thereof, and method of detecting target substance and method of identifying structure of target substance using probe array | CANON KABUSHIKI KAISHA (JP) | 1999-02-03 | — | — | EP | claimed |
| EP-4596719-A2 | SYSTEMS AND METHODS FOR TARGETING DIROFILARIA IMMITIS AND DIROFILARIA REPENS | Smith College (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-3959344-B1 | A KIT FOR TARGETING DIROFILARIA IMMITIS | SMITH COLLEGE (US) | 2025-06-04 | — | — | EP | disclosed |
| US-12285476-B2 | Amino acid sequence derived from S protein of SARS-CoV2 for generating an anti-SARS-CoV-2 antibody | TOAGOSEI CO., LTD. (JP) | 2025-04-29 | — | — | US | disclosed |
| WO-2025063100-A1 | PEPTIDE FRAGMENT AND USE THEREOF | 東亞合成株式会社 | 2025-03-27 | — | — | WO | disclosed |
| WO-2025033255-A1 | PEPTIDE FRAGMENT AND USE THEREOF | 東亞合成株式会社 | 2025-02-13 | — | — | WO | disclosed |
| EP-0438534-A1 | IMMUNOREACTANT CARRIERS HAVING A NOVEL BIOCOMPATIBLE INTERMEDIATE COATING AND PROCESS OF MAKING SAME | COULTER CORPORATION (US) | 1991-07-31 | — | — | EP | disclosed |
| US-4981979-A | IMMUNOLOGY | NEORX CORPORATION (US) | 1991-01-01 | — | — | US | disclosed |
| WO-1990004178-A1 | IMMUNOREACTANT CARRIERS HAVING A NOVEL BIOCOMPATIBLE INTERMEDIATE COATING AND PROCESS OF MAKING SAME | COULTER CORPORATION (US) | 1990-04-19 | — | — | WO | disclosed |
| US-4536391-A | REACTING A PLASMIN HEAVY CHAIN WITH UROKINASE IN THE PRESENCE OF A COUPLING AGENT | OTSUKA PHARMACEUTICAL CO. (JP) | 1985-08-20 | — | — | US | disclosed |
| EP-0109653-A2 | Process for preparing urokinase complex | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10953073-B2 | XTEN conjugate compositions and methods of making same | XPA, TXLNA, NGLY1 | MGLL 3726/4885TLR9 3602/4885PSMB8 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.